Journal
CANCER MEDICINE
Volume 11, Issue 1, Pages 183-193Publisher
WILEY
DOI: 10.1002/cam4.4371
Keywords
breast cancer; cisplatin; combo therapies; immune response; proton exchanger inhibitors
Categories
Funding
- Italian Ministry of Health Cinque per mille
- Associazione Italiana per la Ricerca sul Cancro [IG15434, IG 23201]
- Italian Ministry of Health [GR-2016-02363630]
Ask authors/readers for more resources
The study found that the combination of cisplatin and proton exchanger inhibitors is significantly more effective in treating triple negative breast cancer, while using proton exchanger inhibitors alone is more effective in another type of breast cancer. These treatments also lead to changes in the number of immune cells, which have a positive impact on tumor infiltration.
Triple negative breast cancers (TNBCs) are very aggressive and have a poor prognosis due to lack of efficacious therapies. The only effective treatment is chemotherapy that however is frequently hindered by the occurrence of drug resistance. We approached this problem in vitro and in vivo on a triple negative and a hormone sensitive breast cancer cell lines: 4T1 and TS/A. A main defense mechanism of tumors is the extrusion of intracellular protons derived from the metabolic shift to glycolysis, and necessary to maintain an intracellular pH compatible with life. The resulting acidic extracellular milieu bursts the malignant behavior of tumors and impairs chemotherapy. Therefore, we investigated the efficacy of combined therapies that associate cisplatin (Cis) with proton exchanger inhibitors, such as esomeprazole (ESO) and 5-(N-ethyl-N-isopropyl)amiloride (EIPA). Our results demonstrate that in the 4T1 triple negative model the combined therapy Cis plus EIPA is significantly more effective than the other treatments. Instead, in the TS/A tumor the best therapeutic result is obtained with ESO alone. Remarkably, in both 4T1 and TS/A tumors these treatments correlate with increase of CD8(+ )T lymphocytes and dendritic cells, and a dramatic reduction of M2 macrophages and other suppressor myeloid cells (MDSC) in the tumor infiltrates.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available